Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Ipsen

Evaluate

Thumbnail
July 28, 2023

Go or no go? Biogen and Astellas head towards key Pdufas

Thumbnail
July 04, 2023

US FDA approval and panel tracker: June 2023

Article image
Vantage logo
June 30, 2023

Cymabay soars as Genfit hits an itch hitch

Article image
Vantage logo
May 31, 2023

Go or no go? Key FDA decisions for Argenx and Regeneron

Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.

Article image
Vantage logo
April 11, 2023

Pfizer's fortunes overshadow first-quarter dealmaking

Aside from Seagen, small takeouts dominate the first quarter.

Article image
Vantage logo
April 06, 2023

The strange battle for Exelixis

A welcome return of shareholder activism sees a curious battle develop for the one-hit wonder Exelixis.

Article image
Vantage logo
March 03, 2023

The sun sets on Exelixis’s pipeline in a product

After Cabometyx’s latest clinical setback Exelixis might have to turn to follow-on projects for future growth.

Article image
Vantage logo
February 02, 2023

A renewed push into early bladder cancer

Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.

Article image
Vantage logo
January 11, 2023

Biopharma’s bolt-on bonanza is set to continue

With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?

Article image
Vantage logo
January 10, 2023

Amgen saves biopharma’s buyout year

December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.

Article image
Vantage logo
January 09, 2023

JP Morgan 2023 – day one sees buyers make the most of straitened times

Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up